High concordance has been reported between tumor tissue NGS and cfDNA in studies investigating the presence of EGFR alterations in NSCLC, multiple genes in pancreaticobiliary cancers (KRAS, TP53, APC, FBXW7, SMAD4), exons 12–13 of KRAS in colorectal cancer, BRAF V600E and KIT mutations in melanoma, and BRAF, EGFR, KRAS, and PIK3CA across a variety of advanced cancers [20–23]. This evidence concerns the gene KRAS and melanoma.